Xeltis

Transformative vascular implants. Addressing major life-threatening diseases, backed by Nobel-winning science.

Founded 2006

The Netherlands 82 employees Total: $195.50M Health Care, Health and Wellness +1

General Information

Company Name Xeltis

Founded Year 2006

Location

The Netherlands

Employees 82

Industries Health Care, Health and Wellness, Medical Devices

Business Model B2B, B2D

Revenue Model Product Sales, Licensing, Service Fee

Offices as of Sep 2026

Eindhoven، ، North Brabant 5612 AR، NL, Eindhoven، ، North Brabant 5612 AR، NL

Social

BounceWatch is an independent company data service, not affiliated with Xeltis. To contact Xeltis, visit xeltis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Xeltis compare?

A PDF of Xeltis and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Xeltis soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

From the desk

Is Xeltis on your competitive set?

Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.

Book a 7-day Readout

Discover More

The Netherlands Market

Market Signals All Companies

Health Care

Industry Signals All Companies in The Netherlands

Xeltis Alternatives

All Signals Trend Reports

About Xeltis

Xeltis, a pioneering force in Health Care and Medical Devices, is transforming treatments for major life-threatening diseases. Founded in 2006, this company is headquartered in The Netherlands and is developing artificial vessels and valves that gradually integrate with patients' own living tissue. Grounded in Nobel-winning science, Xeltis is addressing critical needs in vascular health.

The most recent funding round, a €12.50M Series D investment on 14 August 2023, showcases strong backing from an impressive consortium of investors, including Kurma Partners, VI Partners, DaVita Venture Group, European Innovation Council, Ysios Capital, China Grand Pharmaceutical and Healthcare Holdings, and EQT Life Sciences.

This substantial financial endorsement underlines Xeltis' innovative potential and reflects significant confidence in their disruptive approach to health care solutions.

Business keywords: transformative vascular implants, artificial blood vessels, polymer-based restorative devices, cardiovascular treatment, hemodialysis vascular access, coronary artery bypass graft surgery, pulmonary heart valves, clinical-stage medical devices, university spin-offs, venture capital funding, nobel-winning science, advanced polymer technology, tissue regeneration

Services & Products

Development of novel vascular implants

Research and development in polymer-based medical devices

Clinical trial operations

Vascular access solutions for dialysis

Cardiovascular surgery innovations

Target Customers

Cardiovascular surgeons Hospitals and healthcare providers Patients requiring vascular surgeries Renal dialysis centers

Funding Rounds & Investors (11)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Round	€20.50M	7	VI Partners, DaVita +5	28 Jul 2026
Series D	€12.50M	7	Kurma Partners, VI Partners +5	14 Aug 2023
Series D	€32.00M	4	DaVita Venture Group, Invest-NL +2	21 Feb 2023
Series D	€15.00M	1	China Grand Pharmaceutical and Healthcare Holdings	09 Aug 2022
Grant	€2.50M	1	European Innovation Council	21 Dec 2021
Venture Round	€12.50M	1	European Innovation Council	21 Dec 2021
Debt Financing	€15.00M	1	European Investment Bank	22 Nov 2021
Series D	€10.50M	1	LSP	06 Sep 2019
Series C	€45.00M	4	Kurma Partners, VI Partners +2	15 Nov 2017
Series B	€3.00M	3	Kurma Partners, VI Partners +1	17 Dec 2015

View All 11 Funding Rounds

Latest News

View All

Dutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves replaced by pa... — Eu-startups

Dutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves replaced by patients’ own tissue

Eu-startups Jul 28, 2026

How EQT uses AI to see the startup world differently

Tech Nov 20, 2025

Axelera AI and Xeltis secure EU scaleup funding

Ioplus.nl Apr 03, 2025

Xeltis Alternatives & Competitors

View All Alternatives

Xeltis vs

Novostia Switzerland

Heart valves for life, for patients of any age, including children

15 employees

Health Care, Medical Devices

Compare Xeltis vs Novostia

Xeltis vs

Solenic Medical Inc. United States

Technology That Keeps You Moving

17 employees

Biotechnology, Health Care

Compare Xeltis vs Solenic Medical Inc.

Xeltis vs

SyMap Medical

Crafting advanced, catheter-based systems for renal denervation therapy aimed at treating hypertensi...

Series E

1 employees

Biotechnology, Health Care

View all alternatives

FAQ About Xeltis

Transformative vascular implants. Addressing major life-threatening diseases, backed by Nobel-winning science.

Xeltis was founded in 2006.

Xeltis is headquartered in The Netherlands. As of Sep 2026, it also has offices in Eindhoven، ، North Brabant 5612 AR، NL, Eindhoven، ، North Brabant 5612 AR، NL.

Xeltis operates in Health Care, Health and Wellness and Medical Devices. Its work centres on transformative vascular implants, artificial blood vessels, polymer-based restorative devices and cardiovascular treatment. Its customers include Cardiovascular surgeons, Hospitals and healthcare providers and Patients requiring vascular surgeries.

Xeltis has a B2B and B2D business model. Its revenue comes from Product Sales, Licensing and Service Fee.

Xeltis has approximately 82 employees.

Xeltis has completed 11 funding rounds, raising a total of $195.50M.

Xeltis offers: Development of novel vascular implants, Research and development in polymer-based medical devices, Clinical trial operations, Vascular access solutions for dialysis, Cardiovascular surgery innovations.

Top alternatives and competitors to Xeltis include Novostia, Solenic Medical Inc., SyMap Medical, Hillrom, Hummingbird Bioscience. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Xeltis and Novostia are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Xeltis, https://bouncewatch.com/company/xeltis, updated 25 September 2026. When citing, please name BounceWatch and link this page.